Jul 09, 2019 8:00 am EDT Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial
Jun 03, 2019 6:55 am EDT Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure
May 20, 2019 8:30 am EDT Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May 15, 2019 7:30 am EDT Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update
May 06, 2019 7:00 am EDT Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai
Apr 18, 2019 5:30 pm EDT Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
Mar 21, 2019 7:00 am EDT Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
Mar 05, 2019 9:25 am EST Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai